Unknown

Dataset Information

0

Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients.


ABSTRACT: One way to enhance quality of life for patients with metastatic sarcoma is to maximize time off chemotherapy-a chemotherapy-free interval. While image-guided ablation of sarcoma metastases may reduce the need for chemotherapy, it remains unknown how long ablation could extend the chemotherapy-free interval. The purpose of our study was to determine the chemotherapy-free interval in comparison to overall survival and progression-free survival in sarcoma patients who undergo ablation procedures. An IRB-approved, single institution, HIPAA compliant database was queried for sarcoma patients who underwent image-guided ablation procedures between 2007 and 2018. Patient demographics, histologic subtype, and other clinical characteristics were recorded. Kaplan-Meier analysis was performed to compute median overall survival, median progression-free survival (local and distant), and the median chemotherapy-free interval (systemic and cytotoxic) after ablation. Univariate and multivariate analyses were performed using the log-rank test and Cox proportional-hazards model, respectively. A total of 100 sarcoma patients were included in the analysis. The most common histologic subtype was leiomyosarcoma (38%). Median overall survival after ablation of sarcoma metastases was 52.4 months (95% CI: 46.9-64.0 months). The median systemic chemotherapy-free interval following ablation of sarcoma metastases was 14.7?months (95% CI: 8.6-34.3 months). The median cytotoxic chemotherapy-free interval following ablation of sarcoma metastases was 81.3?months (95% CI: 34.3-median not reached). In conclusion, ablation of sarcoma metastases can provide an extended systemic chemotherapy-free interval of greater than 1 year. Ablation of sarcoma metastases may improve patient quality of life by extending the chemotherapy-free interval.

SUBMITTER: Sutton C 

PROVIDER: S-EPMC7044489 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients.

Sutton Charles C   Zhang Yachao Y   Kim DaeHee D   Yarmohammadi Hooman H   Ziv Etay E   Boas Franz E FE   Sofocleous Constantinos T CT   Tap William D WD   D'Angelo Sandra P SP   Erinjeri Joseph P JP  

Sarcoma 20200214


One way to enhance quality of life for patients with metastatic sarcoma is to maximize time off chemotherapy-a chemotherapy-free interval. While image-guided ablation of sarcoma metastases may reduce the need for chemotherapy, it remains unknown how long ablation could extend the chemotherapy-free interval. The purpose of our study was to determine the chemotherapy-free interval in comparison to overall survival and progression-free survival in sarcoma patients who undergo ablation procedures. A  ...[more]

Similar Datasets

| S-EPMC7596120 | biostudies-literature
| S-EPMC4078140 | biostudies-other
| S-EPMC5698193 | biostudies-literature
| S-EPMC5537124 | biostudies-other
| S-EPMC6393544 | biostudies-literature
| S-EPMC4078155 | biostudies-literature
| S-EPMC8921032 | biostudies-literature
| S-EPMC6689378 | biostudies-literature
| S-EPMC3324186 | biostudies-other
| S-EPMC6058323 | biostudies-literature